Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Semaglutide in type 2 diabetes with chronic kidney disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, semaglutide also significantly reduced the rate of eGFR decline (annual slope difference 1•16 mL/min per 1•73 m², 0•86-1•47), MACE (HR 0•82, 0•68-0•98), and all-cause mortality (HR 0•80, 0•67-0•95)”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Treatment with injectable semaglutide 1 mg once weekly reduced the relative risk for the composite primary outcome (ie, ≥50% eGFR decline, eGFR <15 mL/min per 1•73 m², dialysis or transplant, or death due to kidney disease or cardiovascular disease) by 24% compared with placebo (HR 0•76, 0•66-0•88).26”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Moreover, the GLP-1 receptor agonist, semaglutide reduced the risk of a composite kidney end point in a dedicated kidney outcome trial.11”
From The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025) · cites this paper as [11]
In the citing paper
“semaglutide can reduce the progression of chronic kidney disease in patients with and without diabetes and even in those taking SGLT2 inhibitors [12–14].”
From New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? (2025) · cites this paper as [13]
In the citing paper
“Once-weekly treatment with 1 mg semaglutide reduced the risk of the primary composite outcome by 24% and delayed the progression of kidney dysfunction over a period of 4 years (75).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [75]
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Bikbov, B., Purcell, C. A., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., Adebayo, O. M., Afarideh, M., Agarwal, S. K., Agudelo-Botero, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30045-3 · Cited by 6,648
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationEmpagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citation
Cited by
Items 901–1,000 of 1,871
Cardiovascular Therapeutics at the Crossroads: Pharmacological, Genetic, and Digital Frontiers
Vetrano, E., Caturano, A., Nilo, D., Lorenzo, G. D., Tagliaferri, G., Piacevole, A., Donnarumma, M., Iadicicco, I., Picco, S., Moretto, S. M., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18111703 · Cited by 3
“The FLOW trial [60] provided the first dedicated renal-outcome evidence, showing significant reductions in kidney-disease progression and cardiovascular death in patients with T2DM and CKD.”
The era of combination of nephroprotective agents in CKD is there
Jadoul, M. Y., & Rossing, P. R. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae260 · Cited by 2
“Even more recently, the publication of the FLOW trial re-sults with the glucagon-like peptide 1 receptor agonist semaglu-tide in T2D with CKD [12 ] adds another agent to the armamentar-ium, of course awaiting regulatory approval for the CKD and T2D indication for semaglutide and position in…”
Self-citationRadi, S., Alsolami, H. A., Bader, M. W., Almazmumi, M. K., AlSahafi, A., Habeeballah, J. H., Ibrahim, R. I., Alosaimi, H. A., Alzahrani, J. A., & Ahmed, M. E. (2024) · Cureus · doi:10.7759/cureus.73850 · Cited by 2
Habas, E., Rayani, A., Habas, A., Alarbi, K., Habas, A., Baghi, M., Habas, E., Errayes, E., Hamad, A., & Elzouki, A. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2688578 · Cited by 2
Mohsen, M., Yi, T. W., Faruque, L. I., Ke, C., Cafazzo, J. A., Pham, Q. N., Sridhar, V. S., Levin, A., Abdel-Qadir, H. M., Persson, F., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag163 · Cited by 6
Babroudi, S., & Weiner, D. E. (2025) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2024.10.002 · Cited by 2
Intermuscular Adipose Tissue in CKD: A Window into Muscle Quality and Health?
Demirci, M., Dilaver, R. G., Roshanravan, B., Ikizler, T. A., & Gamboa, J. L. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000745 · Cited by 6
2025 Taiwan consensus recommendations for primary care of chronic kidney disease
Tsai, Y., Wu, P.-Y., Lai, T., Sung, C., Chiu, Y., Hwang, S., Hsu, Y., Wu, M.-S., & Shih, C. (2025) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2025.11.016 · Cited by 4
Wu, J., Lee, K.-W., Huang, S.-C., Chang, H.-Y., & Lin, Y. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113273 · Cited by 2
Ye, L., Tang, P., Wan, H., Zhong, X., Chen, X., Liu, C., & Huang, R. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s581491 · Cited by 3
“9 Moreover, this cardioprotective effect was independent of CKD severity.”
Semaglutide cuts kidney risk in obesity
Giugliano, D., Nicola, L. D., Maiorino, M. I., & Esposito, K. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02494-0 · Cited by 2
Asopa, M., Kamgar, M. K., Wilson, J. M., et al. (2025) · Cureus · doi:10.7759/cureus.83263 · Cited by 2
“Recent advances in pharmacotherapy for metabolic diseases have highlighted the potential of sodium-glucose cotransporter-2 inhibitors (SGLT-2 inhibitors) [3] and glucagon-like peptide-1 receptor agonists (GLP-1RA) [4] in improving patient outcomes.”
Update on clinical heart failure trials
Hoevelmann, J., Tokcan, M., Kulenthiran, S., Abdin, A., Viljoen, C. A., & Böhm, M. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02784-4 · Cited by 2
Lindhardt, R. B., Rasmussen, S. B., Riber, L. P., et al. (2025) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezaf144 · Cited by 2
Athinarayanan, S. J., Bjornstad, P., Shanmugam, P., Weimbs, T., Wolfberg, A., Volek, J. S., Himmelfarb, J., & Johnson, R. L. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71086 · Cited by 3
Cao, J., Dun, Z., Tian, D., Qiao, Z., & Wang, Y. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s580866 · Cited by 2
Should Incretin Agonist-Based Drugs be Considered for First Line Antihypertensive Therapy?
Kylies, D., Dreher, L., & Wenzel, U. O. (2026) · Current Hypertension Reports · doi:10.1007/s11906-026-01374-7 · Cited by 2
Tentolouris, A., Filippatos, C., Tepetes, N.-I., Gavriatopoulou, M., Terpos, E., Briasoulis, Α., Stamatelopoulos, K. S., & Filippatos, T. D. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70841 · Cited by 4
“In the FLOW trial, an RCT of 3533 patients with T2D and CKD (median follow-up 3.4 years), once-weekly semaglutide 1.0 mg reduced major kidney disease events by 24% versus placebo [35].”
InfluentialNavaux, E., La, C., Dufour, S., Huberty, V., Mourabit, Y., Caës, T., Koliakos, N. N., Mikhalski, D., Moine, A. L., & Catalano, C. (2025) · Frontiers in Transplantation · doi:10.3389/frtra.2025.1623096 · Cited by 6
Rørth, R., Gerds, T. A., Kosjerina, V., Carstensen, B., Persson, F., & Rossing, P. R. (2025) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2025.100286 · Cited by 2
Self-citationGeagea, M., Kozaily, E., Buchanan, C. J., Litwin, S. E., & Tedford, R. J. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10601-x · Cited by 1
Yano, Y., Okami, S., Kanegae, H., Oberprieler, N. G., Johannes, C. B., Yamashita, S., Yoshikawa‐Ryan, K., Kovesdy, C. P., Vizcaya, D., & Kashihara, N. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16394 · Cited by 1
“Recent cardiovascular outcome trials 14 – 17 and a kidney outcome trial 18 have shown the benefits of this medication class in reducing the risk of cardiovascular and kidney outcomes.”
Pasqua, M., Doumat, J., Tsoukas, M. A., & Haidar, A. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.10.175 · Cited by 1
Alabi, O., Lan, Z., Huck, D. M., Kijewski, M. F., Park, M.-A., Hainer, J. M., Carre, S. L., Perillo, A., Martell, L., Barrett, L., et al. (2026) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.125.018979 · Cited by 2
Mann, J. F. E., Badve, S. V., Baeres, F. M. M., Belmar, N., Brown‐Frandsen, K., Buse, J. B., Colhoun, H. M., Deanfield, J. E., Engelmann, M. D. M., Hovingh, G. K., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00134-8 · Cited by 5
Self-citationGong, J., Chiu, N., Clinch, K., Qian, Y., Ho, J. E., & Wadhera, R. K. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.04.031 · Cited by 4
GLP‐1RA use improves outcomes post partial nephrectomy in T2DM patients with RCC: A TriNetX study
Kwon, S. H., Wardrop, F., Gonzalez, D., Ryan, F., Khutsishvili, L., Turner, R., Deameh, M. G., & Whalen, M. J. (2026) · BJUI Compass · doi:10.1002/bco2.70169 · Cited by 2
“10 Similarly, the SELECT trial, which enrolled over 17 500 participants with obesity and CVD (without diabetes), reported a significantly slower rate of eGFR decline in the semaglutide arm.”
Warden, B. A., Duell, P. B., Bucheit, J. D., & Purnell, J. Q. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.11.013 · Cited by 1
Rossing, P. R., Lindhardt, M. K., Tikkanen, C. K., Menon, J., Cattin, J., Hunt, B., Malkin, S. J. P., Chubb, B., Damgaard, T., & Borg, R. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-03002-1 · Cited by 5
“…significant differences were observed in glycated hemoglobin (HbA 1c ) and body mass index (BMI) changes in the first 3 years, in urine albumin‐to-creatinine ratio (UACR) reduction during the first 2 years (by 32%, 24% and 34%, respectively), as well as in the first-year change in eGFR [23, 24].”
Self-citationWu, L., Cheng, W., Meng, B., Yan, H., Liu, J., Miao, F., Zhang, T., Zhang, X., Ding, N., Zhao, Y., et al. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.169539 · Cited by 2
Alicic, R. Z., & Neumiller, J. J. (2025) · Cardiology Clinics · doi:10.1016/j.ccl.2024.12.003 · Cited by 1
Increased autoantibodies against incretin indicate poor prognosis in patients with diabetes
Takemoto, M., Zhang, B., Hayashi, A., Yamagata, H., Yoshida, Y., Koshizaka, M., Onishi, S., Yamaga, M., Yoshida, T., Hashimoto, T., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-22337-z · Cited by 2
“Clinical trials have shown the glucose-lowering, cardioprotective, and renoprotective effects of GLP-1 9,16 .”
Abdallah, H., Khalil, M., Mahdi, L., Pietragalla, G., Faienza, M. F., Garruti, G., & Portincasa, P. (2026) · Nutrients · doi:10.3390/nu18142317 · Cited by 1
“Some studies have shown the effects of semaglutide on glycemia and lipid improvement, as well as a cardiovascular beneficial effect, in addition to its anti-obesity management effect [246,247].”
Taal, M. W. (2026) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2026.151692 · Cited by 1
Bale, C., Biradar, V., & Mulay, A. V. (2026) · Chronicle of Diabetes Research and Practice · doi:10.4103/cdrp.cdrp_24_25 · Cited by 1
Androutsopoulou, V. A., Brecher, V., Xanthopoulos, A. V., Avgerinos, D. V., Athanasiou, T., & Magouliotis, D. E. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13070305 · Cited by 1
“Renal protection is increasingly well established: in a dedicated kidney-outcome trial, semaglutide reduced the progression of chronic kidney disease and major kidney events, an effect of particular interest given the high incidence of cardiac surgery-associated acute kidney injury [33].”
Koufakis, T., Popovic, D. S., Karakasis, P., Georgianos, P. I., & Patoulias, D. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2416584 · Cited by 2
“FLOW [7] is the first dedicated kidney outcome trial with a GLP-1 RA to evaluate kidney and CV outcomes and mortality in people with T2D and CKD [defined by an eGFR of 50 to 75 mL/min/1.73 m 2 and a urinary albumin-to-creatinine ratio (UACR) of > 300 and <5000 mg/g or an eGFR of 25 to <50…”
InfluentialA Framework for Risk-Based Implementation of Combination Therapy in CKD: Who, Why, When, and How?
Yeung, E. K., Rangaswami, J., Tuttle, K. R., Grams, M. E., Tangri, N., Vaduganathan, M., & Neuen, B. L. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001158 · Cited by 1
Self-citationSantamaría, R., Escobar, C., Aranda, U., et al. (2026) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2026.501414 · Cited by 1
Management of hypertension in chronic kidney disease
Doulton, T., Swift, P. A., & Hiremath, S. S. (2026) · Clinical Medicine · doi:10.1016/j.clinme.2026.100583 · Cited by 1
Cornelio, C. K., Cowart, K., Perkins, J. B., Alomar, M., Pineda-Gayoso, R., Miranda, A. C., Phan, A. T., & White, R. T. (2026) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70130 · Cited by 5
A Holistic Approach to AKI: Integrating Clinical and Molecular Data in the Human Kidney
Schaub, J. A., Alaba, M. O., & Kretzler, M. (2025) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2025.151663 · Cited by 1
Pecoits-Filho, R., Banerjee, D., Jardine, M., Neuen, B. L., Soler, M. J., Ahmed, S. B., Anderson, L. J., Bavanandan, S., Bansal, S., Burton, J. O., et al. (2026) · Kidney International · doi:10.1016/j.kint.2026.06.044 · Cited by 2
Self-citationGLP-1-based therapies for obesity: Impact on comorbidities or obesity-related diseases
Vilarrasa, N., & Pellitero, S. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2025.107184 · Cited by 1
Smith, E., & Scholey, J. W. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27021033 · Cited by 1
“In addition to approaches to the delivery of ACE2 to the kidneys, the development of MasR peptide or non-peptide agonists may be another new treatment approach to diabetic nephropathy, akin to the approach taken with GLP1 receptor agonists [83].”
Vournas, G., Mourgos, L., Doumas, M. N., Liberopoulos, E. N., Kotsa, K., & Koufakis, T. (2026) · Diseases · doi:10.3390/diseases14020075 · Cited by 2
“…in diabetes management, did not independently influence treatment patterns after adjustment, even though recent evidence from the FLOW trial [20] demonstrated a significant reduction in kidney outcomes and cardiovascular death with semaglutide, underscoring a persistent gap between emerging…”
Elenjickal, E. J., Valson, A. T., Varughese, S., Vincent, L., Fernando, E. M., & Natarajan, G. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1531748 · Cited by 2
Mitochondrial Homeostasis in Diabetic Cardiomyopathy: From Dysfunction to Therapeutic Strategies
Huang, Y., Zou, W., Jiang, X., Cheng, J., & Zheng, J. (2026) · Antioxidants · doi:10.3390/antiox15030399 · Cited by 4
“…to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease) trial revealed that semaglutide significantly reduces the risk of major kidney disease events and cardiovascular outcomes in patients with T2DM and chronic kidney disease, highlighting its organ-protective pleiotropy [168].”
Metabolic Liver Disease Beyond the Liver
Gastaldelli, A., Tacke, F., & Holleboom, A. G. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.12.003 · Cited by 1
CHENG, A. Y. Y., Mottl, A. K., & MAGWIRE, M. L. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01796-7 · Cited by 5
Trends in nephrology: from “supportive care” to CKD combination therapy
He, K., Guo, Y., Yang, C., Johnson, D. W., & Su, G. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag003 · Cited by 1
Late Allograft Loss and Contemporary Cardiorenal Metabolic Therapies
Vinson, A. J., & Matas, A. J. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000726 · Cited by 2
Gallo, G., & Volpe, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf299 · Cited by 1
Position Statement on Cardiometabolic Health Across the Woman's Life Course – 2025
de Oliveira, G. M. M., de Almeida, M. C. C., Valério, C. M., Giuffrida, F. M. A., Espíndola, L. N., Izar, M. C. D. O., Marques-Santos, C., Freire, C. M. V., Albuquerque, C. J. D. M., Chagas, A. C. P., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250615i · Cited by 2
Zhao, K., Zhu, H., Zheng, L., Wang, W., Liu, P., Yu, R., & Ma, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1690036 · Cited by 2
Semaglutide in non-diabetic patients with Fabry disease
Riccio, E., Capuano, I., & Pisani, A. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf088 · Cited by 1
Alali, M., Naveed, A. K., Alnounou, A., Alharami, M., & Nashed, B. (2026) · Cureus · doi:10.7759/cureus.109979 · Cited by 1
“…semaglutide significantly reduced the risk of kidney disease progression and cardiovascular death in patients with type 2 diabetes and chronic kidney disease, highlighting the broad organ-protective potential of GLP-1 receptor agonists in patients with obesity-related metabolic complications [20].”
Carlino, I., Franco, S. D., Colalillo, N., Bisogno, S., Gennari, L., & Palazzuoli, A. (2026) · Biomedicines · doi:10.3390/biomedicines14061289 · Cited by 1
“These findings have been further strengthened by the recently reported FLOW trial, which demonstrated significant kidney protective effects of semaglutide in individuals with diabetic kidney disease [63,72,89–91].”
Negnal, M., Kiel, S., Stracke, S., et al. (2025) · Zeitschrift für Allgemeinmedizin · doi:10.1007/s44266-025-00356-3 · Cited by 1
Management of acute kidney disease in type 2 diabetes: the potential role of GLP-1 RAs and SGLT2-Is
Giugliano, D., Esposito, K., & Nicola, L. D. (2024) · Journal of Nephrology · doi:10.1007/s40620-024-02107-2 · Cited by 3
Athinarayanan, S. J., Bjornstad, P., Shanmugam, P. V., et al. (2025) · medRxiv · doi:10.1101/2025.10.17.25338238 · Cited by 1
Association of GLP-1 Receptor Agonist Use With Chronic Kidney Disease Risk in Type 2 Diabetes
Yen, F., Hsu, C., Hung, Y., Huang, J.-Y., Hwu, C., & Wei, J. C. (2026) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2026.01.035 · Cited by 1
Harris, M., Brown, J., & Renehan, A. G. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03355-8 · Cited by 1
“RCTs demonstrate their bene fi ts beyond weight loss, on reducing the risk of obesity-related co-morbidities such as type 2 diabetes [15], cardiovascular events [16], renal function [17], and osteoarthritis [18].”
Funck, K. L., Borregaard, B., Egstrup, K., Fredslund, E. K., Hansen, T. W., Kallestrup, P., Olsen, M. H., Reventlow, S. D., Rossing, P. R., Sandbæk, A., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-106018 · Cited by 3
“12 We present the design and rationale for the randomised Steno INTEN-CT trial.”
Self-citationOptimizing kidney and cardiovascular protection in an era of multiple effective treatments
Taal, M. W. (2024) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001019 · Cited by 1
Rico-Fontalvo, J. E., Reina, M., Soler, M. J., Unigarro-Palacios, M., Castañeda-González, J. P., Quintero, J. J., Raad-Sarabia, M., de Moraes, T. P., & Daza-Arnedo, R. (2024) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2024-0101pt · Cited by 4
Yang, W., Hao, C., Wang, N., Xie, J., Zhou, B., Yang, Z., Zheng, A., Wei, J., Li, C., Xie, C., et al. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2661854 · Cited by 3
“245,246 Beyond metabolic and cardio-renal domains, emerging evidence points to potential disease-modifying effects of GLP-1RAs in degenerative musculoskeletal conditions, likely mediated through attenuation of chronic meta-inflammation.”
Hasebe, M., Kamido, H., Su, C., Keidai, Y., Yabe, D., & Yoshiji, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70749 · Cited by 2
Natural History of Chronic Kidney Disease in Sickle Cell Disease
Ataga, K. I. (2026) · American Journal of Hematology · doi:10.1002/ajh.70300 · Cited by 1
Lee, Y., Nguyen, F., Anvari, S., Molnar, A. O., Doumouras, A. G., Walsh, M. W., & Hong, D. (2025) · British journal of surgery · doi:10.1093/bjs/znaf168 · Cited by 2
Górriz, J. L., & Navarro‐González, J. F. (2025) · Nephrology Self-Assessment Program · doi:10.58483/nsap.00782024 · Cited by 1
Reversal of advanced diabetic kidney disease in mice treated with a monoclonal anti-VEGFR1 antibody
Qi, Z., Tang, Y., Croy, J. E., Wilson, J. M., Heinz-Taheny, K. M., Credille, K. M., Dey, A., Coşkun, T., Ding, Y., Jaqua, D. L., et al. (2026) · Kidney International · doi:10.1016/j.kint.2026.03.016 · Cited by 2
GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology
Fano, M. D., Haurum, L. L., Andreasen, C. R., Porcellati, F., & Andersen, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70888 · Cited by 5
Reule, S. A., Pickthorn, S., Drake, T., Ishani, A., & Foley, R. (2025) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2025.12.001 · Cited by 1
GLP-1-RA – „New kid on the block“ in der Nephrologie?
Kraft, L., Schanz, M., & Latus, J. (2025) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2420-6176 · Cited by 1
“Demgegenüber blieb die Verbesserung der eGFR in der Semaglutid-Grup-pe über einen deutlich längeren Zeitraum nachweisbar – sowohl auf Basis des Serum-Kreatinins als auch von Cystatin-C oder der kombinierten Berechnung [22].”
Joy, E., & Bonnet, J. P. (2026) · American Journal of Lifestyle Medicine · doi:10.1177/15598276261450530 · Cited by 1
Olabe, J., Garrouste, C., Pereira, B., Colosio, C., Thierry, A., Rérolle, J.-P., Bertrand, D., Jaureguy, M., Goblin, L., Büchler, M., et al. (2025) · Clinical Transplantation · doi:10.1111/ctr.70116 · Cited by 1
Marstrand-Jørgensen, A. B., Sembach, F. E., Ougaard, M. K., Hansen, D., Østergaard, M. V., Hansen, H. H., Dalbøge, L. S., Kaasbøll, O. J., & Christensen, M. S. (2025) · Animal Models and Experimental Medicine · doi:10.1002/ame2.70094 · Cited by 2
Fan, Y., Chen, X., Cai, X., Dong, Y., Liu, C., Chen, Y., Lip, G. Y. H., & Zhu, W. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156678 · Cited by 1
Yang, Y., Huang, J., Wu, J., Li, X., Wang, Y., Chen, H., Qiu, Z., & Zhou, Z. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2506813 · Cited by 2
Restrição proteica na DRC: uma estratégia obsoleta na era moderna
Bawazir, A., Topf, J. M., & Hiremath, S. S. (2025) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2024-po03pt · Cited by 2
“O recente estudo FLOW destacou a eficácia dos agonistas do receptor de GLP-1 na redução do risco de eventos renais e na diminuição do declínio da TFG em pacientes com diabetes tipo 2 e DRC 30 .”
Sen, S., Pai, S., & Harbell, M. W. (2025) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001522 · Cited by 1
Moreno, Ó., Tejera‐Muñoz, A., Tomás‐Gómez, P., Vázquez, F., Soria-Utrilla, V., Roldán‐Sánchez, A. M., Sánchez-Baya, M., Cárdenas‐Salas, J., Timón‐Vázquez, B., Martínez, J. J. G., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71160 · Cited by 2
Kim, M. J., Kim, H. S., Cho, Y. K., Jung, C. H., & Lee, W. J. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112978 · Cited by 1
(2024) · doi:10.1101/2024.08.15.608191 · Cited by 1
“…liraglutide for chronic weight management nearly ten years ago, countless trials have since documented a spectrum of associated benefits, including in conditions as diverse as nonalcoholic steatohepatitis, chronic kidney disease, obesity-related heart failure, and even Parkinson’s disease 42–45 .”
BackgroundCardiorenal outcomes of weight loss interventions in people with CKD and type 2 diabetes
Wilkinson, T. J., Goldney, J., Yates, T. E., Henson, J. J., Zaccardi, F., Khunti, K., Webb, D. R., Papamargaritis, D., & Davies, M. J. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf258 · Cited by 3
“For example, the FLOW (Evaluate Renal Function with Semaglutide Once Weekly) trial found semaglutide reduced the risk of kidney outcomes and death from cardiovascular causes in people with T2DM and CKD [18 ].”
InfluentialIs There a Role for Pentoxifylline in Diabetic Kidney Disease? A Mini Review
Leehey, D. J., & Agarwal, R. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.09.030 · Cited by 1
Saeed, Z. I., & Apovian, C. M. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01369-w · Cited by 2
“Semaglutide also reduced all-cause and CV mortality in this population [48].”
Yau, K., Ray, J. G., Jeyakumar, N., Luo, B., Abdullah, S. S., McArthur, E., Dixon, S. N., Wing, S. L., Clemens, K. K., Castrillon-Ramirez, F., et al. (2025) · Diabetes Care · doi:10.2337/dc24-2811 · Cited by 1
Tirzepatide in Metabolic Diseases: Clinical Efficacy and Safety Beyond Diabetes and Obesity
Dong, S., Xu, Y., Gan, R., Zhang, A., He, J., & Tang, Q. (2026) · Medicinal Research Reviews · doi:10.1002/med.70049 · Cited by 1
“Tirzepatide and semaglutide exhibited the most pronounced effects, with their efficacy being comparable [45, 91, 93, 95].”
Neumiller, J. J., Deng, Y., SWARNA, K. S., Polley, E. C., Herrin, J. S., Galindo, R. J., Umpierrez, G. E., Ross, J. S., Mickelson, M. M., Dryden, K., et al. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.04.007 · Cited by 1
Self-citationKaur, R., & Singh, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71031 · Cited by 1
“The FLOW trial [3] provided the largest absolute contribution (HR 0.76; absolute risk reduction 7.3 percentage points; NNT 14).”
InfluentialPosition Statement on Cardiometabolic Health Across the Woman's Life Course – 2025
de Oliveira, G. M. M., de Almeida, M. C. C., Valério, C. M., Giuffrida, F. M. A., Espíndola, L. N., Izar, M. C. D. O., Marques-Santos, C., Freire, C. M. V., Albuquerque, C. J. D. M., Chagas, A. C. P., et al. (2025) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.61622/rbgo/2025rbgo200 · Cited by 2
Theodorakopoulou, M. P., Miglinas, M., & Jørgensen, M. B. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae207 · Cited by 2
Jansz, T. T., McGovern, A. P., Young, K., Dinsdale, M. M., Cardoso, P., Shields, B. M., Hattersley, A. T., Jones, A. G., Pearson, E. R., Bingham, C., et al. (2026) · The Lancet Primary Care · doi:10.1016/j.lanprc.2026.100139 · Cited by 5
Navigating the Drop in Estimated GFR That We See With Drugs That Modify Cardiorenal Events
Weir, M. R. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.12.007 · Cited by 2
Ji, L., Andersen, J. S., Benamar, M., Ponzani, P., Unnikrishnan, A. G., VINTHER, S. M., & Rea, R. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70895 · Cited by 2
“Findings from the FLOW phase 3b trial showed improvements in glycaemic control and a reduced risk of kidney outcomes and cardiovascular-related death with semaglutide 1.0 mg versus placebo in individuals with T2D and chronic kidney disease [31].”
InfluentialHenriques, J. P., Weckwerth, A. V. B., Sant’Ana, A. C. P., Damante, C. A., Santos, C. F., & Negrato, C. A. (2026) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2026.06.008 · Cited by 5
Brown, A. C., MacLaughlin, H. L., McCafferty, K., Potthoff, S., Greenwood, S. A., Vickerstaff, V., Batterham, R. L., Thomas, R. A. B., Hobbs, C., & Motallebzadeh, R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70900 · Cited by 1
Exploring the impact of semaglutide on renal function
Noor, N., Khatoon, R., & Kumar, D. (2024) · International Urology and Nephrology · doi:10.1007/s11255-024-04215-1 · Cited by 1
Metadata
- Authors
- Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., & Pratley, R.
- Affiliations
- University of Copenhagen (DK)
- Novo Nordisk A/S, Søborg, Denmark.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-11
- Volume
- 391
- Issue
- 2
- Pages
- 109-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4398781461
- Cited by
- 2,099
- References
- 23
- Citations by year
- 2026: 953 · 2025: 863 · 2024: 281
- FWCI
- 551.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- semaglutide, chronic kidney disease, type 2 diabetes, renal failure, estimated glomerular filtration rate decline, cardiovascular mortality, albuminuria, GLP-1 receptor agonists, renal protection, cardiovascular outcomes, albumin-creatinine ratio, kidney transplantation, dialysis, anemia of chronic kidney disease, diabetic nephropathy, SGLT2 inhibitors
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Glucagon-Like Peptides, Female, Glomerular Filtration Rate, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.